{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.8","upperLimit":"53.2","value":"39.7"},{"groupId":"OG001","lowerLimit":"19.1","upperLimit":"62.4","value":"46.0"},{"comment":"The upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG002","lowerLimit":"28.3","upperLimit":"NA","value":"50.1"},{"comment":"The upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG003","lowerLimit":"31.2","upperLimit":"NA","value":"42.2"},{"comment":"The median and 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median and upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG005","lowerLimit":"19.4","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"6.8","upperLimit":"25.2","value":"10.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"116"},{"groupId":"OG003","value":"67"},{"groupId":"OG004","value":"78"},{"groupId":"OG005","value":"31"},{"groupId":"OG006","value":"29"}],"units":"Participants"}],"description":"OS was defined as the time from the first dose of pralsetinib to the date of death due to any causes.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who had RET-fusion positive NSCLC previously treated with platinum-based chemotherapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG000","title":"RET- Fusion Positive NSCLC With Prior Platinum Treatment"},{"description":"Participants who had RET-fusion positive NSCLC previously treated with non-platinum or systemic therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG001","title":"RET-fusion Positive NSCLC With Non-platinum Systemic Treatment"},{"description":"Participants who had RET-fusion positive NSCLC not previously treated with systemic or platinum-based chemotherapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG002","title":"RET-fusion Positive NSCLC With No Prior Systemic or Platinum Treatment"},{"description":"Participants who had RET- mutation positive MTC previously treated with either cabozantinib and/or vandetanib therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG003","title":"RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment"},{"description":"Participants who had RET- mutation positive MTC not previously treated with cabozantinib or vandetanib therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG004","title":"RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment"},{"description":"Participants who had RET-fusion positive TC received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG005","title":"RET-fusion Positive TC"},{"description":"Participants who had other RET-positive solid tumors other than NSCLC and TC received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG006","title":"RET-fusion Positive Solid Tumors Other Than NSCLC and TC"}],"paramType":"MEDIAN","populationDescription":"Efficacy population included all participants who have been exposed to at least one dose of the study drug at the RP2D. As pre-specified in the SAP, OS was to be assessed in participants with RET-fusion positive NSCLC, RET-mutation MTC, RET-fusion TC, and RET-fusion solid tumors other than NSCLC and TC. Hence, only the data for these arms is presented here.","reportingStatus":"POSTED","timeFrame":"Up to approximately 7 years","title":"Phase 2: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}